1. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. (February 2017) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Iglesias, J.; Fernandez-Teruel, C.; Jandali, U.; Soto-Matos, S.M.; Stathis, A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 340 A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors. (September 2015) Authors: Stathis, A.; Hess, D.; Xyrafas, A.; Enoiu, M.; Berardi, S.; Moos, R. Von; Homicsko, K.; Griguolo, G.; Jörger, M.; Mark, M.; Ackermann, C.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. (September 2015) Authors: Garralda, E.; Stathis, A.; Drilon, A.; Boni, V.; Hyman, D.; Calvo, E.; Griguolo, G.; Makker, V.; Doger, B.; Canziani, L.; Varghese, A.M.; Jimenez, E.; Luque, J.; Soto-Matos, A.; Szyldergemajn, S.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF. (1st November 2016) Authors: Mangas, C.; Potrony, M.; Mainetti, C.; Bianchi, E.; Carrozza Merlani, P.; Mancarella Eberhardt, A.; Maspoli‐Postizzi, E.; Marazza, G.; Marcollo‐Pini, A.; Pelloni, F.; Sessa, C.; Simona, B.; Puig‐Butillé, J.A.; Badenas, C.; Puig, S. Journal: British journal of dermatology Issue: Volume 175:Number 5(2016) Page Start: 1030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. (August 2016) Authors: Fiedler, W.; DeDosso, S.; Cresta, S.; Weidmann, J.; Tessari, A.; Salzberg, M.; Dietrich, B.; Baumeister, H.; Goletz, S.; Gianni, L.; Sessa, C. Journal: European journal of cancer Issue: Volume 63(2016) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores. (September 2018) Authors: Broekman, K.E.; Jalving, M.; van Tinteren, H.; Sessa, C.; Reyners, A.K.L. Journal: Cancer treatment reviews Issue: Volume 69(2018) Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Five‐year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Issue 3 (February 2015) Authors: Proebstle, T. M.; Alm, B. J.; Göckeritz, O.; Wenzel, C.; Noppeney, T.; Lebard, C.; Sessa, C.; Creton, D.; Pichot, O. Journal: British journal of surgery Issue: Volume 102:Issue 3(2015:Mar.) Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). (3rd June 2015) Authors: Joerger, M.; Hess, D.; Delmonte, A.; Gallerani, E.; Fasolo, A.; Gianni, L.; Cresta, S.; Barbieri, P.; Pace, S.; Sessa, C. Journal: British journal of clinical pharmacology Issue: Volume 80:Number 1(2015:Jul.) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF. (31st August 2016) Authors: Mangas, C.; Potrony, M.; Mainetti, C.; Bianchi, E.; Carrozza Merlani, P.; Mancarella Eberhardt, A.; Maspoli‐Postizzi, E.; Marazza, G.; Marcollo‐Pini, A.; Pelloni, F.; Sessa, C.; Simona, B.; Puig‐Butillé, J.A.; Badenas, C.; Puig, S. Journal: British journal of dermatology Issue: Volume 175:Number 5(2016) Page Start: 1030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗